Emcure Pharmaceuticals Limited
Records under this name other than the patents Emcure Pharmaceuticals Limited holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 12 patents it holds.
Back to Emcure Pharmaceuticals Limited
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,006,453 | Process for preparation of zolmitriptan Lapsed on the fee record Ended Apr 14, 2023 · From the USPTO record | Lapsed on the fee record | Ended Apr 14, 2023 | From the USPTO record |
| US 8,952,155 | Rilpivirine process Lapsed on the fee record Ended Feb 10, 2023 · From the USPTO record | Lapsed on the fee record | Ended Feb 10, 2023 | From the USPTO record |
| US 7,858,801 | Process for producing enantiomer of amlodipine in high optical purity Lapsed on the fee record Ended Dec 28, 2022 · From the USPTO record | Lapsed on the fee record | Ended Dec 28, 2022 | From the USPTO record |
| US 8,686,165 | Process for preparation of taxane derivatives Lapsed on the fee record Ended Apr 1, 2022 · From the USPTO record | Lapsed on the fee record | Ended Apr 1, 2022 | From the USPTO record |
| US 9,919,993 | Process for preparation of acitrecin Lapsed on the fee record Ended Mar 20, 2022 · From the USPTO record | Lapsed on the fee record | Ended Mar 20, 2022 | From the USPTO record |
| US 8,604,189 | Process for the preparation of Efavirenz Lapsed on the fee record Ended Dec 10, 2021 · From the USPTO record | Lapsed on the fee record | Ended Dec 10, 2021 | From the USPTO record |
| US 8,569,544 | Process for preparation of benzphetamine and its pharmaceutically acceptable salts Lapsed on the fee record Ended Oct 29, 2021 · From the USPTO record | Lapsed on the fee record | Ended Oct 29, 2021 | From the USPTO record |
| US 8,445,688 | Process for producing enantiomer of amlodipine in high optical purity Lapsed on the fee record Ended May 21, 2021 · From the USPTO record | Lapsed on the fee record | Ended May 21, 2021 | From the USPTO record |
| US 9,522,924 | Pyridone derivatives as acid secretion inhibitors and process for preparation thereof Lapsed on the fee record Ended Dec 20, 2020 · From the USPTO record | Lapsed on the fee record | Ended Dec 20, 2020 | From the USPTO record |
| US 9,480,681 | Controlled release formulations of nisoldipine Lapsed on the fee record Ended Nov 1, 2020 · From the USPTO record | Lapsed on the fee record | Ended Nov 1, 2020 | From the USPTO record |